Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Generation of stable PDX derived cell lines using conditional reprogramming.

Borodovsky A, McQuiston TJ, Stetson D, Ahmed A, Whitston D, Zhang J, Grondine M, Lawson D, Challberg SS, Zinda M, Pollok BA, Dougherty BA, D'Cruz CM.

Mol Cancer. 2017 Dec 6;16(1):177. doi: 10.1186/s12943-017-0745-1.

2.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.

3.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.

Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, Ren Y, Zhou F, Adam A, Zinda M, Reimer C, Qing W, Su W, Clark E, D'Cruz CM, Schuller AG.

Oncotarget. 2016 Sep 6;7(36):57651-57670. doi: 10.18632/oncotarget.10859.

4.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.

Mol Cancer Ther. 2015 Nov;14(11):2508-18. doi: 10.1158/1535-7163.MCT-15-0365. Epub 2015 Sep 10.

5.

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL.

Mol Cancer Ther. 2015 Nov;14(11):2441-51. doi: 10.1158/1535-7163.MCT-15-0230. Epub 2015 Sep 8.

6.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

7.

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2015 Feb 10;6(4):2407-20.

8.

c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1.

Cowling VH, D'Cruz CM, Chodosh LA, Cole MD.

Mol Cell Biol. 2007 Jul;27(14):5135-46. Epub 2007 May 7.

9.

Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy.

Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA.

Cancer Res. 2006 Jun 15;66(12):6421-31. Erratum in: Cancer Res. 2007 Jan 15;67(2):844-6.

10.

Developmental stage determines the effects of MYC in the mammary epithelium.

Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA.

Development. 2005 Mar;132(5):1147-60. Epub 2005 Feb 2. Erratum in: Development. 2005 Mar;132(6):1475.

11.

Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland.

D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA, Chodosh LA.

Mol Endocrinol. 2002 Sep;16(9):2034-51.

PMID:
12198241
12.

Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis.

Master SR, Hartman JL, D'Cruz CM, Moody SE, Keiper EA, Ha SI, Cox JD, Belka GK, Chodosh LA.

Mol Endocrinol. 2002 Jun;16(6):1185-203.

PMID:
12040007
13.

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA.

Nat Med. 2001 Feb;7(2):235-9.

PMID:
11175856
14.

Mammary gland development, reproductive history, and breast cancer risk.

Chodosh LA, D'Cruz CM, Gardner HP, Ha SI, Marquis ST, Rajan JV, Stairs DB, Wang JY, Wang M.

Cancer Res. 1999 Apr 1;59(7 Suppl):1765-1771s; discussion 1771s-1772s. Review.

PMID:
10197594
15.

Production and characterization of a soluble, active form of Tva, the subgroup A avian sarcoma and leukosis virus receptor.

Balliet JW, Berson J, D'Cruz CM, Huang J, Crane J, Gilbert JM, Bates P.

J Virol. 1999 Apr;73(4):3054-61.

16.

Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas.

Barr FG, Chatten J, D'Cruz CM, Wilson AE, Nauta LE, Nycum LM, Biegel JA, Womer RB.

JAMA. 1995 Feb 15;273(7):553-7.

PMID:
7530783
17.

Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.

Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG.

Cancer Res. 1994 Jun 1;54(11):2869-72.

Supplemental Content

Loading ...
Support Center